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ABSTRAK
Mortalitas maternal akibat hipertensi mencapai 16% bila dibandingkan dengan penyebab lain seperti sepsis, 
perdarahan maupun abortus. Ibu hamil dengan hipertensi berpotensi mengalami sejumlah komplikasi antara 
lain koagulasi intravaskular diseminata (KID), perdarahan otak, gangguan fungsi hati, dan gagal ginjal akut. 
Sedangkan pada janin dapat berakibat pertumbuhan janin terhambat, prematuritas dan mortalitas perinatal.
Hipertensi pada kehamilan perlu ditatalaksana dengan baik agar dapat menurunkan angka morbiditas serta 
mortalitas ibu dan janin, yaitu dengan menghindarkan ibu dari resiko peningkatan tekanan darah, mencegah 
perkembangan penyakit dan mencegah timbulnya kejang dan pertimbangan terminasi kehamilan jika ibu atau 
janin dalam keadaan bahaya.
Kata kunci: tekanan darah, hipertensi, eklamsia, preeklamsia, ibu hamil, gestasional.
ABSTRACT 
Hypertension-related maternal mortality reaches 16% when it is compared to other causes of maternal 
mortality such as sepsis, bleeding or abortus. Pregnant women with hypertension disorder are at increased risk 
for experiencing numerous complications including disseminated intravascular coagulation (DIC), cerebral 
hemorrhage, liver dysfunction and acute renal failure; while to the fetus, it may cause intrauterine growth 
retardation, prematurity and perinatal mortality.
Hypertension in pregnancy should be managed appropriately to reduce maternal and fetal morbidity and 
mortality rate, i.e. by preventing women from getting the risks of increased blood pressure, preventing disease 
progression and preventing the development of seizure and considering termination of pregnancy in life-
threatening situation for maternal and fetal health.
Key words: blood pressure, hypertension, eclampsia, preeclampsia, pregnant women, gestational.
INTRODUCTION
The prevalence of pregnancy-related 
hypertension in well-developed countries 
varies between 10-20% and it is the most 
important cause of maternal and fetal morbidity 
and mortality.1 Currently, maternal mortality 
due to hypertension reaches 16% in addition 
to other causes such as sepsis, bleeding or 
abortus.2 Pregnant women with hypertension 
are at increased risk for experiencing numerous 
complications such as disseminated intravascular 
coagulation (DIC), cerebral hemorrhage, liver 
dysfunction and acute renal failure; while to 
the fetus, it may cause intrauterine growth 
retardation, prematurity and perinatal mortality.3 
Pathogenesis of preeclampsia (PE) is quite 
complex involving genetic, immunologic and 
environmental factors. The development of PE 
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is categorized into 2 stages including abnormal 
placentation and maternal syndrome.4
The classification of hypertension in 
pregnancy that has been commonly used is 
the one proposed by The National High Blood 
Pressure Education Program Working Group on 
Hypertension in Pregnancy (NHBPEP), in which 
hypertension is defined as blood pressure that 
is ≥140/90 mmHg.5 Numerous problems may 
develop on the management of hypertension 
in pregnancy including indication of treatment, 
target blood pressure that should be achieved, 
maternal and fetal side effects of antihypertensive 
drugs.6 Observational studies in patients with 
mild chronic hypertension demonstrate that 
the risk of pregnancies are: preeclampsia (l0-
25%), abruptio (0.7-l.0%), premature birth less 
than 37 weeks (12-34%) and intrauterine fetal 
growth (8-16%). The risk increases in severe 
chronic hypertension during the first trimester 
since the risk of experiencing preeclampsia 
increases up to 50%. To the fetus, hypertension 
causes increased risk of intrauterine growth 
retardation, prematurity and intrauterine death. 
Moreover, common risks of hypertension such 
as heart failure, encephalopathy, retinopathy, 
cerebral hemorrhage and acute renal failure 
may also occur. However, it should be noted 
that the benefit of hypertension treatment during 
pregnancy depends on the severity of the disease. 
Physiologically, blood pressure begins to 
fall inn the second trimester, which may reach 
mean blood pressure of 15 mmHg lower than the 
systolic blood pressure before the third trimester 
of pregnancy. The fall occurs either in subjects 
with normal blood pressure (normotension) or 
those with chronic hypertension. Hemodynamical 
changes, altered renal anatomy and physiology 
and body adaptation that occur during pregnancy 
cause early detection can be difficult.7
ALTERED RENAL ANATOMY AND FUNCTION 
DURING PREGNANCY
The changes that occur during pregnancy 
include increased kidney size of ±1 cm, increased 
kidney volume by 30% and physiological 
hydronephrosis that appears until 12 weeks 
post-partum. In addition, the physiological 
changes that occur during pregnancy include 
systemic vasodilation characterized by a 
significant reduction in systolic blood pressure 
(SBP) ≥10 mmHg due to local mediators such as 
prostacyclin and nitric oxide (NO), in which the 
lowest blood pressure is reached at the gestational 
age of 22-24 weeks. This condition causes body 
adaptation by increasing the secretion of renin-
angiotensin aldosterone (RAA) that may lead to 
vasoconstriction, volume and plasma retention, 
as well as potassium excretion in the urine.
At the same time, to protect the mother and 
fetus of an excessive increase in the RAA, the 
body will increase the resistance to the effects 
of angiotensin II with a reduced amount of 
angiotensin II receptor accompanied by the 
production of prostacyclin and NO. At 28 
weeks gestation, blood pressure began to rise 
while still under the blood pressure before 
pregnancy. Increase in renal plasma flow (RPF) 
and glomerular filtration rate (GFR) may reach 
45% and experienced a peak in the first trimester 
which causes a decrease in serum creatinine to a 
range of 0.5 - 0.8 mg/dL.4
Current definition of hypertension is 
the one used by the National High Blood 
Pressure Education Program Working Group 
on Hypertension in Pregnancy (NHBPEP), 
i.e. a blood pressure ≥140/90 mmHg or DBP 
≥90 mm Hg, or an increase in SBP ≥30 mmHg 
and/ or DBP >15 mmHg from the previous 
measurement, which is measured twice with an 
interval between measurement of ≥6 hours.8
Ideal blood pressure measurement is 
recommended to be performed at home or known 
as the Ambulatory Blood Pressure Monitoring 
(ABPM) and the Pulse Wave Analysis (PWA) 
measurement.9,10 Some literatures differentiate 
blood pressure based on blood pressure levels, 
namely mild hypertension for SBP between 
140-159 mmHg or DBP between 99-109 mmHg. 
Hypertension is considered to be severe when 
the SBP ≥160 mmHg or DBP ≥110 mmHg.4,11-13 
The purpose of NHBPEP classification is 
to differentiate preeclampsia from eclampsia of 
other hypertensive disorders in pregnancy since 
both preeclampsia and eclampsia have a poor 
prognosis on maternal and fetal morbidity and 
mortality.14 The diagnosis criteria of hypertensive 
disorder in pregnancy are as follows:14,15
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Chronic Hypertension
Chronic hypertension is defined as SBP ≥140 
mmHg or DBP ≥90 mmHg that is observable 
before pregnancy or before the 20th week of 
gestation. It can be found at the gestational 
age of >20 weeks or persist in 12 weeks post-
partum. The incidence of chronic hypertension 
is estimated 1-5% of pregnancies depending on 
age and ethnicity/race. Recent reports reported 
that the incidence occurs on Afro-American race 
and it is 1% for other races.
Gestational Hypertension
It is a hypertension characterized by SBP 
≥140 mmHg or DBP ≥ 90 mmHg that develops 
for the first time at the gestational age of ≥ 20 
weeks, without proteinuria or any signs and 
symptoms of preeclampsia; usually the blood 
pressure back to normal in 42 days post partum. 
Patients with gestational hypertension are at risk 
of having hypertension in their next pregnancy 
and it can develop into preeclampsia. 
Preclampsia
a. Minimal criteria. When there is SBP ≥140 
mmHg or DBP ≥90 mmHg at >20 weeks of 
gestation, along with proteinuria ≥300 mg/24 
hour or ≥ +1 on dipstick urinalysis or protein: 
creatinine ratio in the urine ≥0.3.
b. Additional criteria that support the 
diagnosis. Blood pressure ≥160/110 mmHg, 
proteinuria 2.0 g/24 hour or ≥ +2 on dipstick 
urinalysis, creatinine serum level of >1.2 mg/
dL, platelet count <100,000, microangiopathy 
hemolysis, increased transaminase serum level, 
headache, cerebral or other visual disorders.
Preeclampsia itself can be classified into 
2 categories, namely mild preeclampsia and 
severe preeclampsia. Mild preeclampsia is the 
preeclampsia with SBP <160 mmHg or DBP 
90-<110 mmHg. It is called severe preeclampsia 
when we found one of the following signs in 
the patients: SBP ≥160 mmHg and DBP ≥110 
mmHg, proteinuria ≥5 g/24 hours or 4+ on 
dipstick urinalysis, creatinine serum level >1.2 
mg/dL, microangiopathy hemolysis, oliguria, 
cyanosis and pulmonary edema, increased 
transaminase serum level, other cerebral or 
visual disorders, persistent epigastric pain, 
platelet counts <100,000 cells/mm; increased 
liver enzymes (alanin aminotransferase (ALT) 
or aspartate aminotransferase (AST); hemolysis 
– which is best known as the HELLP syndrome.
Eclampsia
When there is any unexplainable seizure in 
a woman who had preeclampsia.
Preeclampsia Superimposed on Chronic 
Hypertension
The possibility of chronic hypertension 
becomes preeclampsia/eclampsia is 15-
30%.16,17 We should suspect for superimposed 
preeclampsia when we find out the following 
symptoms and laboratory abnormalities: a 
sharp increase of blood pressure (>160/110 
mmHg), severe proteinuria (or 2 gram/day), a 
sudden increase of blood pressure after a period 
of controlled blood pressure and increased 
serum creatinine level over 1.2 mg/dL. The 
management of preeclampsia superimposed on 
chronic hypertension is similar with the general 
management of preeclampsia.
Nagay et al.18 observed phenotypic changes 
in the cells of smooth muscle afferent artery of 
the renal glomerulus in patients with chronic 
hypertension who also experienced preeclampsia. 
By immunohistochemistry, they demonstrated 
the occurrence of reduced contractile protein 
(antimonoclonal smooth miscle cell myosin 
heavy chain isoform antibodies = SM2) in afferent 
glomerular arteries of patients with preeclampsia 
superimposed on chronic hypertension.18,19
DIAGNOSIS OF PREECLAMPSIA
Preeclampsia is characterized by hypertension 
which occurs at >20 gestation, along with 
proteinuria and the symptoms resolve after birth. 
Proteinuria is defined as the excretion of protein 
in the urine of ≥300 mg/24 hour, or protein: 
creatinine ratio ≥0.3, or when there is a persistent 
protein finding of 30 mg/dL on random urinalysis 
(+1 on dipstick urinalysis). Preeclampsia occurs 
in 6% of pregnancies, usually primigravida. 
Moreover, preeclampsia is classified as mild 
and severe preeclampsia, in which both should 
be managed differently.14 The following factors 
increase the risk of preeclampsia:
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1. Risk factors associated with the male partner, 
such as: primigravida, primipaternity, 
age of extremes (too young or too old for 
pregnancy), male partner who had married 
a woman and the woman became pregnant 
and had preeclampsia, limited exposure to 
sperm, insemination donor and oocyte donor. 
2. Risk factors associated with past medical 
history and family history of the disease, 
such as: history of previous preeclampsia, 
chronic hypertension, renal disease, 
obesity, gestational diabetes, type-1 
DM, antiphospholipid antibodies and 
hyperhomocysteinemia
3. Risk factors associated with pregnancy, such 
as: mola hydatidosa, multiple pregnancies, 
urinary tract infection in pregnancy, hydrops 
fetalis.
platelet count). Measurements of AST, ALT and 
LDH enzymes are performed in order to identify 
liver involvement. Urinalysis is necessary to 
identify proteinuria or to quantify the amount of 
protein excretion in the 24-hour urine. Creatinine 
serum level is measured to identify renal function 
in pregnancy and usually decreased level can 
be found. The measurement of uric acid should 
be considered since elevated uric acid level 
is usually used as a marker of preeclampsia 
severity. ECG test is necessary in patients with 
chronic hypertension; while for pregnancies 
without hypertension, the measurement of blood 
glucose and urine culture are also necessary.
Laboratory investigation for patients with 
hypertension in pregnancy include: hemoglobin 
and hematocrit level, platelet count, SGOT/ 
SGPT, LDH serum level, protein urine (24-hour 
urine collection), urinalysis, uric acid, and serum 
creatinine level.20
If new hypertension develops during 
pregnancy in women who are previously healthy 
or in those who are at high risk for preeclampsia, 
an evaluation of short-term hospitalization is 
necessary to distinguish primary hypertension 
from the secondary hypertension using diagnostic 
procedure and subsequently determine the 
classification of hypertension in pregnancy as 
well as execute appropriate treatment.
The assessment of target organ damage 
includes left ventricular hypertrophy, retinopathy 
and renal disease. Some authors suggest 
adrenal ultrasonography and measurement of 
metanephrine and noremetanephrine in the urine 
for all pregnant women when their hypertension 
is caused by pheochromocytoma that may appear 
asymptomatic and may be fatal if the diagnosis 
can not be made before birth.21 USG is useful 
to determine gestational age, fetal development 
and fetal heart rate. Any abnormality in Doppler 
assessment of uterine artery and fetal artery 
as well as the venous Doppler is useful as a 
predictor of preeclampsia development and 
perinatal outcomes.10
MANAGEMENT OF HYPERTENSION IN 
PREGNANCY
The aim of managing hypertension in 
pregnancy is to reduce fetal and maternal 
Tabel 1. Diagnostic criteria for severe preeclampsia4,14
Symptoms •	 Central nervous system disorders such 
as blurred vision or severe headache 
•	 Stretched liver capsule that causes pain 
Signs •	 SBP	≥160	mmHg	or	DBP	≥110	mmHg
•	 Stroke
•	 Intrauterine growth retardation (IUGR)








•	 Liver damage with transaminase serum 
level	≥	2x	of	normal	range	
•	 Platelet	count	<100.000/mm3
•	 Coagulopathy, elongated prothrombin 
time	or	low	fibrinogen	blood	level.	
LABORATORY INVESTIGATION
In addition to blood pressure monitoring, 
laboratory investigation is also necessary to 
monitor any changes in blood, kidney and liver 
that may affect fetal and maternal prognosis. 
The recommended laboratory investigations 
to monitor patients with hypertension in 
their pregnancies are Hb or Ht to observe the 
possibility of hemoconcentration that support the 
diagnosis of gestational hypertension. A very low 
platelet count can be found in HELLP syndrome 
(hemolysis, elevated liver enzyme levels and low 
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morbidity and mortality, i.e. by preventing 
women from getting the risks of increased 
blood pressure, preventing disease progression 
and preventing the development of seizure and 
considering termination of pregnancy if the 
mother or fetus has a life-threatening situation. 
The management of pregnancy with hypertension 
can be seen in Table 2.
In preeclampsia, the hypertension resolves 
to normal condition after birth. However, before 
birth, this condition is unfavorable for the fetus. 
Therefore, although it carries a certain degree 
of risk, conservative treatment is preferable by 
waiting to the best situation when the baby can 
be born in a better condition.
When the range of systolic blood pressure 
is 140-160 or the diastolic blood pressure is 90-
99 mmHg, non-pharmacologic treatment can 
be administered. Short-term hospitalization is 
useful for establishing diagnosis and excluding 
the possibility of preeclampsia. The management 
depends on clinical condition, the severity of 
hypertension, gestational age, maternal and fetal 
risks. It may include close monitoring, physical 
activity restriction, bed rest on the left side. 
For this condition, a normal diet without salt 
restriction is recommended.
PHARMACOLOGICAL TREATMENT
The administration of antihypertensive 
agents should be adjusted individually with the 
risks and benefits for pregnant women. There are 
still debates on when starting antihypertensive 
therapy and on the target blood pressure that 
should be achieved. Severe hypertension (BP 
≥160/100 mmHg) increases cerebrovascular risks 
and therefore, antihypertensive agents should be 
administered.6 However, the use of these agents 
for mild and moderate hypertension is still 
controversial. Some studies show that the use 
of antihypertensive agents in mild hypertension 
can reduce the risk of developing severe 
hypertension; however, there is no difference 
regarding the development of preeclampsia, 
neonatal death, premature birth and low birth 
weight (LBW) infants.22,23
The National High Blood Pressure Education 
Program Working Group on Hypertension 
in Pregnancy (NHBPEP) recommends the 
administration of antihypertensive agents for 
SBP ≥150-160 mmHg or DBP >100-110 mmHg 
or when there is target organ damage, such as 
left ventricular hypertrophy or reduced renal 
function. The desired target blood pressure is 
SBP <140- 150 mmHg and DBP <90-100 mmHg 
Table 2. Management of pregnancy with gestational hypertension12
Degree of hypertension Mild hypertension (140/90 to 149/99 mmHg)
Moderate hypertension 
(150/100 to 159/109 
mmHg)
Severe hypertension 
(160/110 mmHg or higher)
Admit to hospital no no Yes (until blood pressure is 
159/109	mmHg	or	lower)
Treat no with	oral	labetalol	as	first-line treatment to keep:
With	oral	labetalol	as	first-
line treatment to keep:
•	 diastolic blood pressure 
between	80-100	mmHg
•	 systolic blood pressure 
less	than	150	mmHg
•	 diastolic blood pressure 
between	80-100	mmHg
•	 systolic blood pressure 
less	than	150	mmHg
Measure blood pressure not more than once a week at least twice a week at least four times a day
Test for proteinuria at each visit using 
automated	reagent-strip	
reading device or urinary 
protein creatinine ratio
at each visit using 
automated	reagent-strip	
reading device or urinary 
protein creatinine ratio
daily using automated 
reagent-strip	reading	device	
or urinary protein creatinine 
ratio
Blood tests only those for routine 
antenatal care
test kidney function 
electrolytes full blood count, 
transaminases bilirubin
Do not carry out further 
blood tests if no proteinuria 
at subsequent visits
Test at presentation and 
then monitor weekly:
kidney function electrolytes 
full blood count, 
transaminases bilirubin
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or mean arterial pressure (MAP) <105-125 
mmHg. There has not been any definitive and 
complete data on the safety of target therapy for 
blood pressure treatment in pregnant women with 
hypertension.10,24
In patients with chronic hypertension who 
are being pregnant and having high blood 
pressure, their previous treatment should be 
continued. However, in those with slightly 
high blood pressure, the treatment must be 
given with caution and dose reduction should 
be employed whenever necessary. Based on 
data of some studies, it has been demonstrated 
that the use of antihypertensive agents for mild 
hypertension may reduce the development of 
severe hypertension, but show no difference on 
the development of preeclampsia, neonatal death, 
premature birth and low birth weight (LBW) 
infants.22,23
Extremely low blood pressure may develop 
risk of reduced utero-placental perfusion, which 
may disrupt fetal development. However, there 
has not been sufficient convincing evidence on 
the benefit of mild hypertension treatment in 
pregnancy since the number of studied cases 
is still very low and therefore, it is not enough 
to demonstrate the benefit of reduced obstetric 
complication rate.
 Systolic blood pressure of more than 170 
or diastolic blood pressure higher than 110 
mmHG in pregnant woman must be considered 
as a medical emergency and the patient is 
suggested to have hospital care. A patient with 
such condition must have her blood pressure 
reduced as soon as possible. Many doctors do 
not give any drug until the limit of diastolic 
blood pressure reaches >105-110 mmHg or 
when the systolic blood pressure has reached 
160 mmHg, a limit in which complication 
of cerebral hemorrhage usually takes place. 
However, in some conditions, the limit is not so 
accurate considering that the previous diastolic 
pressure is less than 75 mmHg. In gestational 
hypertension (without proteinuria), the limit of 
blood pressure that calls for treatment usually is 
above 140 mmHg systolic blood pressure or 80 
mmHg diastolic blood pressure. In those who 
have hypertension and proteinuria or who have 
symptoms or who have signs of target organ 
damage (chronic hypertension), the drugs can 
be given to achieve the normal blood pressure. 
There are 2 types of antihypertensive drugs, 
namely for acute or emergency situation, which 
usually needs parenteral or oral treatment.
Table 3. Management of pregnancy with preeclampsia12
Degree of hypertension Mild hypertension (140/90 to 149/99 mmHg)
Moderate hypertension 
(150/100 to 159/109 
mmHg)
Severe hypertension 
(160/110 mmHg or higher)
Admit to hospital yes yes yes
Treat no with	oral	labetalol	as	first-line treatment to keep:
with	oral	labetalol	as	first-
line treatment to keep:
•	 diastolic blood pressure 
between	80-100	mmHg
•	 systolic blood pressure 
less	than	150	mmHg
•	 diastolic blood pressure 
between	80-100	mmHg
•	 systolic blood pressure 
less	than	150	mmHg
Measure blood pressure at least four times a day at least four times a day more than four times a 
day, depending on clinical 
circumstances






Blood tests monitor using the following 
tests twice a week: kidney 
function, electrolytes, full 
blood count, transaminases, 
bilirubin
monitor using the following 
tests three times a 
week: kidney function, 
electrolytes, full blood count, 
transaminases, bilirubin
monitor using the following 
tests three times a 
week: kidney function, 
electrolytes, full blood count, 
transaminases, bilirubin
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Side effects: dysrhythmia, weakness, sedation, depression, reduced mental stability, 
dry mouth, decrease in libido, parkinsonism, and hyperprolactinemia, increased serum 
transaminase level and hemolytic anemia




The administration of MgSO4 in pregnant women who had received CCB may cause severe 
hypotension and neuromuscular blockade








Labetolol (Risk factor: C) is a combination of alpha and beta adrenoceptor antagonist with 
vasodilation	effect,	can	reduce	blood	pressure	without	lowering	uteroplacental	blood	flow.




Diuretics The use of diuretics as antihypertensive drugs is permitted only if it has been used for a 
long	period	of	time	before	pregnancy.
Loop diuretics, particularly furosemide (risk factor: C) is indicated for severe heart failure, 
pulmonary	edema	or	oliguria	and	if	there	is	a	risk	of	hyperbilirubinemia	in	newborns.	
The	 use	 of	 HCT	 (hydrochlorothiazide)	 (B)	 may	 cause	 side	 effects	 of	 neonatal	
thrombocytopenia, jaundice, maternal pancreatitis, hypokalemia, hyponatremia, in which 
some studies show that the side effect is similar with those who do not receive diuretic 
treatment.
Dosing:		HCT	12.5-50	mg/day
Spironolactone is contraindicated for pregnancy due to its antiandrogenic effect as observed 
in	animal	experimental	studies.	
ACE	inhibitor	and	Angiotensin	
II receptor (ARB) antagonists
Risk	factor:	C	on	the	1st	trimester	and	D	on	the	2nd	and	3rd	trimester
It has risks of oligohydroamnion, intrauterine growth retardation, pulmonary hypoplasia, 
contracture of joints, neonatal renal failure, hypotension
It carries potential risk for any woman who is planning a pregnancy
The parenteral drugs include intravenous 
injection of abetalol, hydralazine and calcium 
antagonists. Methyldopa 250 mg twice daily 
can be increased up to maximal 4 gram daily. 
Labetalol can be given 100 mg twice daily and 
maximum 400 mg daily. Atenolol, a beta blocker, 
which no effect of alpha blocker is associated 
with reduced placental and fetal blood flow 
during the birth when it is given starting from 
the early pregnancy. Labetalol, an alpha and 
beta blocker, can maintain uteroplacental blood 
flow in maximal condition. A beta blocker drug 
used for mild hypertension may increase the 
risk of having small-for-gestational-age infants 
(with a relative risk of 1.35 on 95% confidence 
interval), a risk that is not higher compared to 
other antihypertensive drugs.
More experiences have been found on 
using calcium antagonists, which have been 
proven relatively safe for pregnancy. Long-
acting nifedipine (maximum dose of 120 mg/
day) and non-dihydropiridin, i.e. verapamil can 
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be given. However, FDA does not accept fast-
acting nifedipine as a treatment for emergency 
hypertension as well as the sub-lingual treatment 
as some evidences have demonstrated that the 
treatment may cause excessive reduction in 
blood pressure. It can be concluded from studies 
on treatment of hypertension in pregnancy that 
the selection of antihypertensive treatment 
should depend on experiences and knowledge 
of doctor who is treating the patient, particularly 
in terms of the maternal and fetal effect of the 
drug. Although there is no clinical study that 
provides any evidence of how much reduction in 
blood pressure is considered to be optimal, many 
have suggested a target systolic blood pressure 
of 140-150 mmHg and diastolic blood pressure 
of 90-100 mmHg. In pregnant women who have 
experienced target organ damage, it is suggested 
to reduce the blood pressure to less than 140/90 
mmHg until it reaches 120 and 80 mmHg.
INDICATION FOR OUTPATIENT AND 
HOSPITAL MANAGEMENT
According to BCRCP Obstetric Guideline 11 
Hypertension in pregnancy 2006, the following 
are indications for outpatient and hospital 
management of hypertension in pregnancy:3
1. Indications for outpatient assessment: 
SBP <140 mmHg and DBP <90 mmHg, 
proteinuria ≤1+ on dipstick urinalyisis on 
one occasion, no target organ damage and 
normal platelet counts. Weekly office visits.
2. Indications to consider hospitalization.
SBP ≥140 mmHg and/or DBP ≥90 mmHg, 
repeated proteinuria >1+, creatinine >30 
mg/mmol, hyperuricemia, platelet count 
<100,000, any adverse features, ultrasound 
evidence of oligohydroamnios or inadequate 
fetal growth.
3. Indication for conservative management and 
termination of pregnancy
Indication for conservative management: 
• Gestational age < 34 weeks
• Stable and well-controlled blood 
pressurel (SBP <160 mmHg/ DBP <110 
mmhg) with atwo antihypertensive 
agents on submaximal dose
• Platelet count ≥100,000
• Proteinuria ≤2+ on dipstick (<1 g/day)
• Good fetal condition (on USG, stress 
test)
Indication for termination of pregnancy:
• Gestational age >34 weeks
• Severe or refractory hypertension >24 
hours
• Pulmonary edema 
• Refractory renal failure 
• T h r o m b o c y t o p e n i a ,  w o r s e n i n g 
coagulopathy
• Eclampsia with neuroprogressive 
symptoms
• Progressive reduction of liver function
• Placental rupture
• Fetal distress 
• Evidences of IUGR or hydramnion
POST PARTUM HYPERTENSION
Hypertension may develop after birth with a 
peak on the 3rd – 6th day due to mobilization of 
extracellular fluid that occur during pregnancy 
and a continuation of hypertension in pregnancy. 
The risks of developing post partum hypertension 
may arise in pregnancy with preeclampsia, 
premature birth, multipara women with a high 
level of uric acid and blood urea nitrogen (BUN). 
Some literatures explain that severe 
hypertension, which occurs both during 
pregnancy and after birth, should be treated. 
Methyldopa should be avoided after birth due 
to a risk of post-natal depression. The common 
first-line agents are atenolol, nifedipin or ACE 
Inhibitor whenever other antihypertensive agents 
are necessary. Antihypertensive treatment for 
preeclampsia lasts for approximately 2 weeks; 
while for gestational hypertension, it lasts less 
than a week.
Preeclampsia is a risk factor for post-partum 
thromboemboli; while other risk factors include 
obesity, bed rest of >4 days after birth and 
Caesarian section. Prevention of thromboemboli 
should be considered unless it is proven to be 
ineffective.15,25
CONCLUSION
A pregnant mother with hypertension has 
potential risks to have some complications, 
such as: disseminated intravascular coagulation 
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(DIC), cerebral hemorrhage, liver dysfunction 
and acute renal failure. Moreover, for the 
fetus, it may cause intrauterine fetal growth 
retardation, prematurity and perinatal mortality. 
The β-adrenergic agonist, namely methyldopa 
(risk factor: B) is the first-line antihypertensive 
drug in pregnancy. Although there is no clinical 
study that provides any evidence of how much 
reduction in blood pressure is considered to be 
optimal, many have suggested a target systolic 
blood pressure of 140-150 mmHg and diastolic 
blood pressure of 90-100 mmHg. In pregnant 
women who have experienced target organ 
damage, it is suggested to reduce the blood 
pressure to less than 140/90 mmHg until it 
reaches 120 and 80 mmHg.
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